Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,004.00 at Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price reduced by Truist Financial from $1,126.00 to $1,004.00 in a research report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other brokerages also recently issued reports on REGN. Barclays cut their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,044.48.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $733.59 on Wednesday. The company’s 50-day moving average is $756.46 and its 200-day moving average is $966.75. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market capitalization of $80.61 billion, a PE ratio of 18.15, a PEG ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals has a fifty-two week low of $693.00 and a fifty-two week high of $1,211.20.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Sachetta LLC raised its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at about $26,000. Fairfield Financial Advisors LTD bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $37,000. Finally, Ashton Thomas Private Wealth LLC acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $39,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.